[go: up one dir, main page]

DE69722608D1 - Hsv-mutant-1716 zur behandlung von mesotheliomen - Google Patents

Hsv-mutant-1716 zur behandlung von mesotheliomen

Info

Publication number
DE69722608D1
DE69722608D1 DE69722608T DE69722608T DE69722608D1 DE 69722608 D1 DE69722608 D1 DE 69722608D1 DE 69722608 T DE69722608 T DE 69722608T DE 69722608 T DE69722608 T DE 69722608T DE 69722608 D1 DE69722608 D1 DE 69722608D1
Authority
DE
Germany
Prior art keywords
mutant
mesotheliomas
hsv
treating
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69722608T
Other languages
English (en)
Other versions
DE69722608T2 (de
Inventor
Susanne Moira Brown
Alasdair Roderick Maclean
Nigel William Fraser
Bruce Paul Randazzo
Steven Albelda
Larry Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Wistar Institute of Anatomy and Biology
Original Assignee
University of Glasgow
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601507.8A external-priority patent/GB9601507D0/en
Priority claimed from GBGB9623365.5A external-priority patent/GB9623365D0/en
Application filed by University of Glasgow, Wistar Institute of Anatomy and Biology filed Critical University of Glasgow
Publication of DE69722608D1 publication Critical patent/DE69722608D1/de
Application granted granted Critical
Publication of DE69722608T2 publication Critical patent/DE69722608T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DE69722608T 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen Expired - Lifetime DE69722608T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9601507.8A GB9601507D0 (en) 1996-01-25 1996-01-25 Treatment of non-neuronal cancer using HSV mutant
GB9601507 1996-01-25
GB9623365 1996-11-09
GBGB9623365.5A GB9623365D0 (en) 1996-11-09 1996-11-09 Non-neuronal cancer treatment
PCT/GB1997/000232 WO1997026904A1 (en) 1996-01-25 1997-01-27 Treatment of non-neuronal cancer using hsv mutant

Publications (2)

Publication Number Publication Date
DE69722608D1 true DE69722608D1 (de) 2003-07-10
DE69722608T2 DE69722608T2 (de) 2004-04-29

Family

ID=26308525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722608T Expired - Lifetime DE69722608T2 (de) 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen

Country Status (6)

Country Link
US (3) US20050226850A1 (de)
EP (2) EP0895476B1 (de)
AT (1) ATE241994T1 (de)
AU (1) AU1550797A (de)
DE (1) DE69722608T2 (de)
WO (1) WO1997026904A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
EP1150696B1 (de) * 1999-02-05 2006-05-10 Arch Development Corporation Genetische manipulierte herpesviren zur behandlung von tumoren
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
WO2001019380A2 (en) 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
WO2004078206A1 (en) 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
EP1606411B1 (de) 2003-03-27 2008-12-10 Ottawa Health Research Institute Mutante vesicular stomatitis viren und deren verwendungen
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
RU2461630C2 (ru) 2005-03-07 2012-09-20 Робартс Рисерч Инститьют Применение комбинации вируса миксомы и рапамицина для терапевтического лечения
CN101203186B (zh) 2005-05-03 2011-05-18 西安大略大学 口腔装置和与之联合使用的试剂盒
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
AU2009237353B2 (en) 2008-04-15 2014-10-23 Trudell Medical International Swallowing air pulse therapy mouthpiece and method for the use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
DK0675961T3 (da) * 1992-03-31 2003-03-24 Arch Dev Corp Behandling af tumorigen sygdom med en modificeret HSV
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant

Also Published As

Publication number Publication date
EP1314430A1 (de) 2003-05-28
AU1550797A (en) 1997-08-20
WO1997026904A1 (en) 1997-07-31
EP0895476B1 (de) 2003-06-04
US20110195053A1 (en) 2011-08-11
EP0895476A1 (de) 1999-02-10
US20070292394A1 (en) 2007-12-20
US20050226850A1 (en) 2005-10-13
ATE241994T1 (de) 2003-06-15
DE69722608T2 (de) 2004-04-29

Similar Documents

Publication Publication Date Title
DE69722608D1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
NO20003230D0 (no) Inhibering av RAF-kinase ved anvendelse av symmetrisk og usymmetrisk substituerte difenylureaforbindelser
ES2086997T3 (es) Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
ATE236262T1 (de) Rekombinanter schweinepocken-virus
ATE238790T1 (de) Verwendung von pramipexole als neuroschutzmittel
DE59409565D1 (de) Verfahren zur Verbesserung der Sicherheit von Frankiermaschinen
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
DE69527204D1 (de) Behandlung von krebs durch verwendung von hsv-mutanten
AU2305295A (en) Use of serotonin antagonists (5HT3) for treating fibro myalgia
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
NO20002504L (no) Adenovirusvektorer og fremgangsmÕte for Õ redusere homologe rekombinasjonsfenomener
NO954896D0 (no) Aromatiske acetylcholinesteraseinhibitorer
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
NO953201L (no) Silylerte acetylcholinesteraseinhibitorer
DE69433978D1 (de) Methode der spezifischen abschaltung von genen durch dna-methylierung
DE69003920D1 (de) Sättigung von Einsatzgas zum Dampfkracken.
DE3880453D1 (de) Vorwaermung von kohlenwasserstoff/wasserdampf-gemischen.
FI961380L (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition